FondaparinSodiuM; Fondaparinux SodiuM Shaida; Fondaparinux sodium N-4;
FondaparinSodiuM; Fondaparinux SodiuM Shaida; Fondaparinux sodium N-4;
Ayyukan Halittu Fondaparinux
| Bayyana | Fondaparinux sodium shine mai hanawar Xa inhibitor mai dogaro da thrombin. |
| Masu alaƙaCategories | Hanyar sigina >> Metabolic enzymes/proteases >> Factor Xa Bincike yankunan >> cututtuka na zuciya da jijiyoyin jini |
| manufa | Factor Xa[1] |
| In vitrokaratu | Fondaparinux sodium shine farkon sabon maganin ƙwanƙwasa wanda ke zaɓen factor Xa.Don Fondaparinux, ƙimar IC50 (anti-Xa IU / ml) na monocytes da aka kunna (ac-M) shine 0.59 ± 0.05, kuma ƙwayoyin da aka samu monocyte (MMP) shine 0.17 ± 0.03 [2]. |
| A cikin vivobincike | Fondaparinux sodium yana da layin layi, bayanin martaba na pharmacokinetic mai dogaro da kashi, wanda ke ba da amsa mai faɗi sosai.Fondaparinux sodium yana da 100% bioavailability, yana da saurin fara aiki, yana da rabin rayuwar sa'o'i 14 zuwa 16, kuma yana iya ci gaba da tsayayya da thrombosis a cikin sa'o'i 24.Magungunan ba ya shafar lokacin prothrombin ko lokacin thromboplastin da aka kunna, kuma baya shafar aikin platelet ko tarawa [1]. |
| Magana | [1].Bauer KA.da al.Fondaparinux sodium: mai zaɓin mai hana factor Xa.Am J Health Syst Pharm.2001 Nov 1; 58 Suppl 2: S14-7.[2].Ben-Hadj-Khalifa S, et al.Tasirin hana haɓakar coagulation daban-daban na fondaparinux, enoxaparin da heparin marasa ƙarfi a cikin samfuran sel na ƙarni na thrombin.Jini Coagul Fibrinolysis.2011 Yuli; 22 (5): 369-73. |
Sinadarai da kaddarorin jiki na Fondaparinux
| Tsarin kwayoyin halitta | Saukewa: C31H53N3Na10O49S8 |
| Nauyin kwayoyin halitta | 1738.16 |
| PSA | 900.82000 |
Fondaparinux wani sabon nau'in maganin antithrombotic ne wanda FDA ta amince da shi bayan heparin da ƙananan nauyin kwayoyin heparin don magani da rigakafin nau'in thrombosis na arteriovenous.
Alamomi: Ana amfani da Fondaparinux ga marasa lafiya da ke yin babban tiyatar orthopedic na ƙananan gaɓɓai, irin su karaya, babban tiyatar gwiwa ko maye gurbin hip, don hana thromboembolism venous.Ana amfani da shi don kula da marasa lafiya tare da angina maras tabbas ko marasa ƙarfi na ST-segment na haɓakar ƙwayar cuta na myocardial wanda ke yin gaggawa (<120 minutes) magani mai haɗari (PCI) ba tare da nuni ba.Ana amfani dashi don kula da marasa lafiya tare da ST-segment elevation myocardial infarction wanda ke amfani da thrombolysis ko da farko ba su karbi wasu nau'i na farfadowa na reperfusion ba.
1) Ci gaba da haɓaka kasuwa na Glaxo zai sanya shi a cikin ainihin matsayin magunguna a cikin hanyar asibiti na Ma'aikatar Lafiya ta gaba, sake fasalin farashin Hukumar Raya da Gyara ta ƙasa, da inshorar likita na Ma'aikatar Inshorar Jama'a.
A, Samfurin bai riga ya shiga inshorar likita na ƙasa ba.A cikin 2010, daidaitawar inshorar likita ya shiga cikin inshorar likitancin gida na larduna 16.Tallace-tallacen suna cikin matakin farko kuma a hankali za su maye gurbin kasuwar heparin mai ƙarancin ƙwayar cuta;lardunan inshorar likita: Shaanxi, Shanxi, Mongoliya ta ciki, Liaoning, Tibet, Yunnan, Guangdong, Guangxi, Hainan, Jiangsu, Gansu, Fujian, Jiangxi, Henan, Hubei, Beijing.
B, Alamun har yanzu suna karuwa.GSK a halin yanzu yana da alamomi 3 a cikin asibitin.Misali, alamun stent an yarda da su ne kawai.Sauran heparins ba su samuwa.Aikace-aikacen asibiti na stent yana ƙaruwa da 30% kowace shekara.Tare da amincewa da sababbin alamu, tallace-tallace zai karu.A cikin ka'idar, duk cututtukan da ake bi da su ta samfuran jerin samfuran heparin ana iya bi da su ta wannan samfurin.
C, Farashin fa'ida, mafi ƙarancin farashin wannan samfurin a cikin kasuwar Amurka shine dalar Amurka 132 kowanne, a China yuan 168, farashin gida ba zai faɗi ba.Idan kun yi fitarwa, kasuwar duniya tana da faffadan sarari;
2) Ƙofar fasaha yana da girma, an haɗa albarkatun kasa a cikin matakai 75, kuma alamar ta ƙare don shekaru 5 (lalacewa a cikin 2014).Wasu masana'antun ba su amince da shi ba.Haɗin yana da matukar wahala.Ba za a yi shi a cikin ƙasa da shekaru 10 ba.Zagayowar yana da tsawo, mai wahala, da zuba jari.babba.Akwai 'yan fafatawa a cikin gida, kuma masu fafatawa na kasashen waje suna da tsadar albarkatun kasa.Manufarmu ita ce ci gaba da rage farashin kayan da aka yi da maye gurbin Glaxo a samar da albarkatun kasa.
An amince da Hengrui Pharmaceuticals Fondaparinux a matsayin kwaikwayo na farko a kasar Sin 2018.
Guangdong Runxing Biotechnology Co., Ltd. yana da fitarwa na shekara-shekara na kilogiram 210 na fondaparinux sodium ci-gaba na matsakaicin N3, wanda za a gabatar a cikin 2018.
MYLAN IRELAND ne ya kirkiro Fondaparinux.A halin yanzu, Hengrui Pharmaceuticals, Borui Pharmaceuticals, Haisco.
JIN DUN Medical yaCancantar ISO kuma ya cika ka'idodin samar da GMP, ƙwararrun ƙwararrun haɗaɗɗun ƙwayoyi na cikin gida da na waje tare da ƙwararrun ƙwarewa don jagorantar R&D na kamfani.
TECHNOL OGY AMFANIN
●High Matsi Catalytic Hydrogenation.Babban Matsi na Hydrogenolysis Reaction.Maganin Cryogenic (<-78% C)
●Aromatic Heterocyclic Synthesis
●Maganar Sake Shiryawa
●Matsalar Chiral
●Heck, Suzuki,Negishi,Sonogashira .Gignard Reaction
Kayan aiki
Our Lab yana da daban-daban na gwaji da kuma gwaji kayan aiki, kamar: NMR (Bruker 400M), HPC, Chiral-HPLC, LC-MS, LC-MS/MS (API 4000) , IR, UV, GC, GC-MS, Chromatography, Microwave Synthesizer, Parallel Synthesizer, Bambance-bambancen Scanning Calorimeter (DSC), Electron Microscope...
Ƙungiyar R&D
Jindun Medical yana da rukuni na ƙwararrun ma'aikatan R&D, kuma yana ɗaukar ƙwararrun masana harhada magunguna na cikin gida da na waje don jagorantar R&D, yana sa ƙirarmu ta fi dacewa da inganci.
Mun taimaka wa manyan kamfanonin harhada magunguna na cikin gida da yawa, kamarHansoh, Hengrui da HEC Pharm.Anan zamu nuna sashinsu.
Hali na Farko na Farko:
Lambar Waya: 110351-94-5
Hali na Musamman na Biyu:
Lambar Waya: 144848-24-8
Halin Hali na Uku:
Lambar Waya: 200636-54-0
1.Keɓance Sabbin Matsakaici ko APIs.Daidai da raba shari'ar na sama, abokan ciniki suna da buƙatun takamaiman Matsakaici ko APIs, kuma ba za su iya samun samfuran da ake buƙata ba a kasuwa, sannan za mu iya taimakawa don Keɓancewa.
2.Haɓaka Tsari don Tsofaffin Kayayyaki.Ƙungiyarmu za ta taimaka don ingantawa da haɓaka irin wannan samarwa wanda hanyar amsawa ta tsufa, farashin samarwa yana da yawa, kuma ingancin ya yi ƙasa.Za mu iya samar da cikakkun takardun shaida don canja wurin fasaha da haɓaka tsari, taimakawa abokin ciniki don samar da ingantaccen aiki.
Daga maƙasudin miyagun ƙwayoyi zuwa INDs, JIN DUN Medical yana ba kumafita na R&D keɓaɓɓen tsayawa ɗaya tasha.
JIN DUN Medical ya dage kan ƙirƙirar ƙungiyar tare da mafarkai, yin samfura masu daraja, ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwaƙƙwaran, masu tsattsauran ra'ayoyi, masu tsauri, da kuma fita gabaɗaya don zama amintaccen abokin tarayya kuma abokin abokan ciniki!
